Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Picard Medical, Inc. securities during the specified Class Period, highlighting potential compensation for affected investors [1][2]. Group 1: Class Action Details - The class action lawsuit pertains to securities purchased between September 2, 2025, and October 31, 2025 [1]. - Investors who purchased Picard Medical securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Process and Participation - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by April 3, 2026, to represent the class in court [1][3]. Group 3: Allegations Against Picard Medical - The lawsuit alleges that defendants made materially false and misleading statements and failed to disclose adverse facts about Picard's business and operations [5]. - Specific allegations include involvement in a fraudulent stock promotion scheme, insider trading through offshore accounts, and omission of critical information regarding stock price manipulation [5]. Group 4: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in previous years [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Picard Medical, Inc. due to allegations of securities law violations, encouraging affected investors to come forward [2][4]. Group 1: Legal Investigation and Claims - The law firm is reminding investors of the April 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against Picard Medical [2]. - Allegations against Picard Medical include involvement in a fraudulent stock promotion scheme and misleading public statements regarding the company's financial health [4]. Group 2: Stock Performance and Impact - On October 24, 2025, Picard Medical's shares closed at $5.31, a significant drop from $13.20 on October 23, 2025, representing a decline of $7.89 per share or approximately 59.8% in a single trading session [5]. Group 3: Firm Background - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its establishment in 1995, with offices in New York, Pennsylvania, California, and Georgia [3].

New York, New York--(Newsfile Corp. - February 6, 2026) - Clear Ads, an advertising agency, released a step-by-step implementation guide for sellers looking to connect AI agents to Amazon's advertising platform through the newly launched Ads MCP Server open beta.Amazon announced the open beta of its Ads Model Context Protocol (MCP) Server on February 2 at the IAB Annual Leadership Meeting. The server acts as a translation layer that converts natural language prompts into structured API calls, allowing AI p ...

Key Takeaways The New York Times Company topped Q4 estimates with EPS of $0.89 and revenues up 10.4% to $802.3M.NYT added about 450K digital-only subs, while digital ARPU rose to $9.72 on pricing shifts and plan upgrades.NYT saw digital ads jump 24.9% and guided Q1 for 14-17% digital-only sub revenue growth.The New York Times Company (NYT) continued its strong performance in the fourth quarter of 2025, with results surpassing expectations for both the top and bottom lines. Adjusted earnings came in at 89 ce ...

Bardeen also said the company generated approximately $551 million of free cash flow in 2025, attributing the result primarily to “robust AOP” and a capital-efficient model, along with lower cash taxes related to a change in tax law for R&E expenditure deductions and net proceeds from the sale of excess land at a printing facility.Chief Financial Officer Will Bardeen reported that full-year total revenue increased about 9%, as gains in digital were partially offset by ongoing declines in print. Digital subs ...

Core Insights - The New York Times Company reported fourth-quarter earnings and revenue that exceeded analyst expectations, but weaker first-quarter guidance negatively impacted investor sentiment, leading to a more than 7% drop in shares during premarket trading [1] Financial Performance - Adjusted earnings per share were $0.89, surpassing the consensus estimate of $0.86 [1] - Revenue increased by 10.4% year over year to $802.3 million, exceeding analyst expectations of $785.68 million [1] Subscription and Advertising Revenue - Digital subscription revenue rose by 13.9% to $381.5 million, driven by the addition of approximately 450,000 net digital-only subscribers during the quarter, bringing total subscribers to 12.78 million [2] - Digital advertising revenue surged by 24.9% to $147.2 million, supported by strong marketer demand and expanded ad inventory [2] Profitability Metrics - Operating profit increased by 10.2% to $161.6 million, while adjusted operating profit rose by 12.8% to $192.3 million [3] - Adjusted operating margin expanded to 24.0%, up roughly 50 basis points from a year earlier [3] Future Guidance - The company forecasts first-quarter 2026 digital-only subscription revenue growth of 14% to 17% and total subscription revenue growth of 9% to 11% [3] - Digital advertising revenue is expected to grow in the high-teens to low-twenties percentage range [3]

New York, New York--(Newsfile Corp. - February 4, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, is honored to celebrate the passage of the Mikaela Naylon Give Kids A Chance Act. Mikaela, like so many other children, courageously battled pediatric cancer - specifically Osteosarcoma. Her legacy through this legislation will accelerate critical opportunities for research and therapeutic access for other children an ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

New York Times Co. (NYT) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $0.8 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1.14%. A quarter ago, it was expected that this newspaper publisher would post earnings of $0.54 per share when it actually produced earnings of $0.59, delivering a surprise of +9.26%.Over the last four quarters, ...

The New York Times Company (NYSE:NYT) Q4 2025 Earnings call February 04, 2026 08:00 AM ET Company ParticipantsAnthony DiClemente - SVP of Investor RelationsBenjamin Soff - Director of Equity ResearchDoug Arthur - Managing DirectorJason Bazinet - DirectorKannan Venkateshwar - Managing Director of US Media, Cable and Telecom Equity ResearchKutgun Maral - DirectorMeredith Kopit Levien - President and CEOThomas Yeh - Executive Director of Equity ResearchWill Bardeen - EVP and CFOConference Call ParticipantsDavi ...